Timothy J. Ley, Washington University School of Medicine (IMAGE)
Caption
Eight in 10 patients with acute myeloid leukemia relapse after remission, and for most of them there's no reliable way to predict relapse. But new research by Timothy J. Ley, MD, and colleagues at Washington University in St. Louis suggests that performing genetic profiling while a patient is in remission can help physicians assess response to treatment and determine whether aggressive, follow-up treatment is necessary.
Credit
Mark Katzman
Usage Restrictions
Credit to Mark Katzman
License
Licensed content